|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/09/21 Cell MedX Corp. 10-Q 2/28/21 56:2.8M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-Q Cell Medx Corp. - Form 10-Q SEC Filing HTML 522K
2: EX-10.32 Loan December 14, 2020 HTML 20K
3: EX-10.33 Loan December 23, 2020 HTML 20K
4: EX-10.34 Loan January 21, 2021 HTML 20K
5: EX-10.35 Loan February 16, 2021 HTML 20K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 19K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 19K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 16K
16: R1 Document and Entity Information HTML 64K
17: R2 Condensed Consolidated Balance Sheets HTML 100K
18: R3 Condensed Consolidated Balance Sheets - HTML 23K
Parenthetical
19: R4 Condensed Consolidated Statements of Operations HTML 86K
20: R5 Condensed Consolidated Statement of Stockholders' HTML 85K
Deficit
21: R6 Condensed Consolidated Statements of Cash Flows HTML 92K
22: R7 Organization and Nature of Operations HTML 23K
23: R8 Related Party Transactions Disclosure HTML 35K
24: R9 Inventory Disclosure HTML 19K
25: R10 Other Current Assets Disclosure HTML 18K
26: R11 Equipment Disclosure HTML 24K
27: R12 Revenue Disclosure HTML 29K
28: R13 Notes and Advances Payable Disclosure HTML 48K
29: R14 Share Capital Disclosure HTML 49K
30: R15 Related Party Transactions Disclosure: Schedule of HTML 26K
Amounts Due to Related Parties (Tables)
31: R16 Related Party Transactions Disclosure: Schedule of HTML 25K
Transactions with Related Parties (Tables)
32: R17 Equipment Disclosure: Change in book value of the HTML 24K
equipment (Tables)
33: R18 Revenue Disclosure: Schedule of Revenue and HTML 29K
Associated Costs (Tables)
34: R19 Notes and Advances Payable Disclosure: Schedule of HTML 38K
Short-term Loans and Advances Outstanding (Tables)
35: R20 Share Capital Disclosure: Schedule of Stock Option HTML 26K
Activity (Tables)
36: R21 Share Capital Disclosure: Schedule of Stock HTML 22K
Options Outstanding (Tables)
37: R22 Share Capital Disclosure: Schedule of Warrant HTML 26K
Activity (Tables)
38: R23 Share Capital Disclosure: Schedule of Warrant HTML 24K
Details (Tables)
39: R24 Organization and Nature of Operations (Details) HTML 20K
40: R25 Related Party Transactions Disclosure: Schedule of HTML 33K
Amounts Due to Related Parties (Details)
41: R26 Related Party Transactions Disclosure: Schedule of HTML 29K
Transactions with Related Parties (Details)
42: R27 Inventory Disclosure (Details) HTML 21K
43: R28 Other Current Assets Disclosure (Details) HTML 21K
44: R29 Equipment Disclosure: Change in book value of the HTML 27K
equipment (Details)
45: R30 Revenue Disclosure: Schedule of Revenue and HTML 43K
Associated Costs (Details)
46: R31 Notes and Advances Payable Disclosure: Schedule of HTML 44K
Short-term Loans and Advances Outstanding
(Details)
47: R32 Notes and Advances Payable Disclosure (Details) HTML 58K
48: R33 Share Capital Disclosure (Details) HTML 42K
49: R34 Share Capital Disclosure: Schedule of Stock Option HTML 31K
Activity (Details)
50: R35 Share Capital Disclosure: Schedule of Stock HTML 27K
Options Outstanding (Details)
51: R36 Share Capital Disclosure: Schedule of Warrant HTML 25K
Activity (Details)
52: R37 Share Capital Disclosure: Schedule of Warrant HTML 31K
Details (Details)
54: XML IDEA XML File -- Filing Summary XML 91K
15: XML XBRL Instance -- cmxc-20210228_htm XML 765K
53: EXCEL IDEA Workbook of Financial Reports XLSX 46K
10: EX-101.CAL XBRL Calculations -- cmxc-20210228_cal XML 62K
11: EX-101.DEF XBRL Definitions -- cmxc-20210228_def XML 254K
12: EX-101.LAB XBRL Labels -- cmxc-20210228_lab XML 451K
13: EX-101.PRE XBRL Presentations -- cmxc-20210228_pre XML 384K
14: EX-101.SCH XBRL Schema -- cmxc-20210228 XSD 143K
55: JSON XBRL Instance as JSON Data -- MetaLinks 175± 247K
56: ZIP XBRL Zipped Folder -- 0001393905-21-000193-xbrl Zip 89K
| Certification |
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending February 28, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: April 9, 2021
/s/ Frank McEnulty
Chief Executive Officer
(Principal Executive Officer)
C:
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 4/9/21 | 424B3 | ||
| For Period end: | 2/28/21 | |||
| List all Filings | ||||